Lantheus (NASDAQ:LNTH) was downgraded by equities research analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Tuesday.
A number of other research analysts have also recently weighed in on the stock. Credit Suisse Group boosted their target price on shares of Lantheus from $19.00 to $23.00 and gave the company a “neutral” rating in a research note on Friday, November 3rd. Jefferies Group restated a “buy” rating and set a $22.00 price target on shares of Lantheus in a research note on Thursday, October 12th. Wells Fargo & Company upgraded shares of Lantheus from a “market perform” rating to an “outperform” rating in a research note on Thursday, November 2nd. Zacks Investment Research upgraded shares of Lantheus from a “hold” rating to a “strong-buy” rating and set a $26.00 price target on the stock in a research note on Tuesday, November 7th. Finally, ValuEngine cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, December 1st. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $24.50.
Lantheus (NASDAQ LNTH) opened at $20.60 on Tuesday. The company has a debt-to-equity ratio of -3.41, a current ratio of 2.96 and a quick ratio of 2.46. The firm has a market cap of $755.75, a PE ratio of 17.99, a price-to-earnings-growth ratio of 1.60 and a beta of 0.94. Lantheus has a 52 week low of $7.95 and a 52 week high of $24.10.
In related news, CFO John W. Crowley sold 6,755 shares of the company’s stock in a transaction that occurred on Friday, October 13th. The shares were sold at an average price of $18.41, for a total transaction of $124,359.55. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, SVP Timothy G. Healey sold 11,314 shares of the company’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $21.51, for a total transaction of $243,364.14. The disclosure for this sale can be found here. Insiders have sold a total of 29,986 shares of company stock worth $625,488 over the last 90 days. 2.30% of the stock is currently owned by corporate insiders.
Several hedge funds have recently made changes to their positions in the stock. Marshall Wace North America L.P. increased its holdings in Lantheus by 1,214.5% during the 2nd quarter. Marshall Wace North America L.P. now owns 1,054,170 shares of the medical equipment provider’s stock worth $18,975,000 after acquiring an additional 973,977 shares during the period. Vanguard Group Inc. increased its holdings in Lantheus by 87.5% during the 2nd quarter. Vanguard Group Inc. now owns 1,478,350 shares of the medical equipment provider’s stock worth $26,093,000 after acquiring an additional 689,954 shares during the period. State Street Corp increased its holdings in Lantheus by 3,932.8% during the 2nd quarter. State Street Corp now owns 617,014 shares of the medical equipment provider’s stock worth $10,891,000 after acquiring an additional 601,714 shares during the period. Peregrine Capital Management LLC bought a new stake in Lantheus during the 3rd quarter worth approximately $8,062,000. Finally, Ameriprise Financial Inc. bought a new stake in Lantheus during the 2nd quarter worth approximately $7,396,000. Institutional investors own 91.91% of the company’s stock.
WARNING: This piece of content was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece of content on another site, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://sportsperspectives.com/2017/12/21/lantheus-lnth-rating-lowered-to-hold-at-bidaskclub.html.
Lantheus Holdings, Inc is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging.
Receive News & Ratings for Lantheus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantheus and related companies with MarketBeat.com's FREE daily email newsletter.